Notably, the proportion of Foxp3+CD4+ Tregs was markedly decreased in the Se@MI-treated group, further supporting the notion that Se@MI reshapes the tumor immune microenvironment by mitigating immune suppression (Figures 5B–D). Here, FOXP3 is linked to neoplasm.